Sharekhan

Akums Drugs and Pharmaceuticals Ltd

Wed 21/05/2025,16:11:46 | NSE : AKUMS

₹ 568.053.60 (0.64%)

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

Open

₹ 561.60

Previous Close

₹ 564.45

Volume

205439

Mkt Cap ( Rs. Cr)

₹8940.77

High

₹ 582.00

Low

₹ 561.10

52 Week High

₹ 1175.90

52 Week Low

₹ 405.00

Book Value Per Share

₹ 180.08

Dividend Yield

0.00

Face Value

₹ 2.00

What’s Your Call?

Collective community sentiment on Akums Drugs and Pharmaceuticals Ltd

Your Vote -

Buy

69.57%

Hold

17.39%

Sell

13.04%

69.57%

23 users have voted

Market Depth

How many stocks are available to buy or sell and at what prices.

Buy Order Quantity

100%

Sell Order Quantity

0%

Bid Price

Qty

568.05

19

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

19

Bid Price

Qty

0.00

0

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

0

Option Chain

Analyzes market sentiment, predicts Akums Drugs and Pharmaceuticals Ltd' movement.

NO_RECORD_FOUND

News

Media spotlight triggers stock stock attention, sentiment.

  • Akums Drugs & Pharma - Board Meeting Intimation

    19 May 2025, 4:24PM Akums Drugs and Pharmaceuticals Limited has informed the Exchange about Board Meeting to be held on 26-May-2025 to inter-alia consider and approve the
  • Akums Drugs & Pharma - Board Meeting Intimation for Consideration And Approval Of Un-Audited (Standalone & Consolidated) Fina

    19 May 2025, 4:22PM Akums Drugs And Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/05/2025 ,inter alia,
  • Akums Drugs & Pharma - Monitoring Agency Report

    14 May 2025, 12:15PM Monitoring Agency Report
  • Akums Drugs & Pharma - Announcement under Regulation 30 (LODR)-Monitoring Agency Report

    14 May 2025, 12:14PM Monitoring Agency Report
  • Akums Drugs & Pharma has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2025

    9 Apr 2025, 3:00PM As of March 2025, 75.26% is owned by Indian Promoters, 22.01% by Public and 2.73% by Non Promoters-Non Public. <p align=justify> Institutional holds 1
  • Akums Drugs & Pharma - Certificate under SEBI (Depositories and Participants) Regulations, 2018

    7 Apr 2025, 1:31PM Akums Drugs and Pharmaceuticals Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
  • Akums Drugs & Pharma - Trading Window-XBRL

    29 Mar 2025, 5:10PM Akums Drugs and Pharmaceuticals Limited has informed the Exchange about Closure of Trading Window
  • Akums Drugs & Pharma - Trading Window

    29 Mar 2025, 5:03PM Akums Drugs and Pharmaceuticals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Tradin
  • Akums Drugs & Pharma - General Updates

    26 Mar 2025, 1:29PM Akums Drugs and Pharmaceuticals Limited has informed the Exchange about General Updates
  • Akums Drugs & Pharma - Resignation Of Senior Management Personnel

    26 Mar 2025, 1:20PM Resignation of Senior Management Personnel.
  • Akums Drugs & Pharma - Shareholders meeting

    18 Mar 2025, 4:11PM Akums Drugs and Pharmaceuticals Limited has submitted the Exchange a copy Srutinizers report of Postal Ballot
  • Akums Drugs & Pharma - Shareholder Meeting / Postal Ballot-Scrutinizer\s Report

    18 Mar 2025, 3:42PM Voting Results of the Postal Ballot along with the Scrutinizer Report.
  • Akums Drugs & Pharma - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    5 Mar 2025, 6:06PM Schedule of Analyst and Investor Meet
  • Akums Drugs & Pharma - Analysts/Institutional Investor Meet/Con. Call Updates

    4 Mar 2025, 12:25PM Akums Drugs and Pharmaceuticals Limited has informed the Exchange about Schedule of meet
  • Akums Drugs & Pharma - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    4 Mar 2025, 12:29PM Schedule of Analyst and Investor Meet
  • Akums Drugs & Pharma - Analysts/Institutional Investor Meet/Con. Call Updates

    1 Mar 2025, 5:47PM Akums Drugs and Pharmaceuticals Limited has informed the Exchange about Schedule of meet
  • Akums Drugs & Pharma - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    1 Mar 2025, 5:51PM Intimation of Schedule of the Analysts/Investor Meet (group meet).

Key fundamentals

Evaluate the intrinsic value of Akums Drugs and Pharmaceuticals Ltd stock 

Name March-24
Assets 370.164
Liabilities 370.164
Equity 28.613
Gross Profit -126.658
Net Profit -165.451
Cash From Operating Activities 247.907
NPM(%) -11.45
Revenue 1444.119
Expenses 1570.777
ROE(%) -5.83

Shareholding Pattern

Corporate Action

XD-Date Dividend-Amount Dividend-% Dividend Yield(%GE) Price on that day

Peers

Other companies within the same industry or sector that are comparable to Akums Drugs and Pharmaceuticals Ltd

Company Price Price (% change) pe(x) EV/EBITDA(x) ROE(%) ROCE(%)
Albert David Ltd 810.15 -0.84 26.88 321.86 301.39 0.62
Lotus Eye Hospital and Institute Ltd 74.06 0.78 308.58 1172.81 14.01 0.68
Vaishali Pharma Ltd 12.85 -1.15 428.33 604.51 2.76 0.00
Astec Lifesciences Ltd 701.25 -1.59 0.00 1105.86 -687.11 0.00

Company Info

Our Company was incorporated as a public limited company under the Companies Act, 1956 as `Akums Drugs and Pharmaceuticals Limited', pursuant to a certificate of incorporation dated April 19, 2004 issued by the RoC. Our Company received a certificate for commencement of business issued by the RoC dated May 13, 2004.Major Events and Milestones:2004-Incorporation of the Company-Established first plant for oral dosage commissioned at 19, 20, 21, sector 6A, Haridwar, Uttarakhand2007-Established dedicated manufacturing site for oral liquid dosage at 22, Sector 6A, Sidcul, Haridwar, Uttarakhand and sterile products at 2,3,4,5, Sector 6B, SIDCUL, Haridwar, Uttarakhand2009-Incorporated Maxcure Nutravedics Limited to venture into nutraceuticals2010-Dedicated a facility for hormones at 48, Sector 6A, SIDCUL, Haridwar, Uttarakhand-Dedicated a facility for cosmetics and dermatology at 47, Sector 6A, SIDCUL, Haridwar, Uttarakhand-Incorporated Akumentis Healthcare Limited to venture into branded formulations2011-Innovated bi-layered sustained release tablets for the first time2012-Acquired Pure and Cure Healthcare Private Limited to expand capacity and capabilities2013-Innovated tablet-in-tablet sustained release tablets for the first time-Acquired Malik Lifesciences Private Limited manufacturing sites to expand capacity and capabilities-Expanded into the African market2015-Expanded into the Asian market-Established research and development laboratory in Mumbai, Maharashtra to venture into regulated market2016-Maxcure Nutravedics Limited received US-NSF certification2019-Investment by Ruby QC Investment Holdings Pte. Ltd. in our Company to become a minority shareholder2021-Acquired Parabolic Drugs to form Akums Lifesciences Limited and ventured into APIs-Acquisition of a facility at Kotdwar, Uttarakhand by Akums Healthcare Limited2022-Plant at 19, 20, 21, Sector 6A, SIDCUL, Haridwar, Uttarakhand and plant at 2, 3, 4,5, Sector 6B, SIDCUL, Haridwar, Uttarakhand accredited European Union-Good Manufacturing Practices, qualifying for exports to European markets-Acquisition of a facility in Haridwar, Uttarakhand by Akums Healthcare Limited and a facility in Baddi, Himachal Pradesh by Pure and Cure Healthcare Private Limited2023-Acquisition of another facility in Baddi, Himachal Pradesh by Pure and Cure Healthcare Private Limited-Merger of Akums Lifesciences Limited with Pure and Cure Healthcare Private Limited

Our Company was incorporated as a public limited company under the Companies Act, 1956 as `Akums Drugs and Pharmaceuticals Limited', pursuant to a certificate of incorporation dated April 19, 2004 issued by the RoC. Our Company received a certificate for commencement of business issued by the RoC dated May 13, 2004.Major Events and Milestones:2004-Incorporation of the Company-Established first plant for oral dosage commissioned at 19, 20, 21, sector 6A, Haridwar, Uttarakhand2007-Established dedicated manufacturing site for oral liquid dosage at 22, Sector 6A, Sidcul, Haridwar, Uttarakhand and sterile products at 2,3,4,5, Sector 6B, SIDCUL, Haridwar, Uttarakhand2009-Incorporated Maxcure Nutravedics Limited to venture into nutraceuticals2010-Dedicated a facility for hormones at 48, Sector 6A, SIDCUL, Haridwar, Uttarakhand-Dedicated a facility for cosmetics and dermatology at 47, Sector 6A, SIDCUL, Haridwar, Uttarakhand-Incorporated Akumentis Healthcare Limited to venture into branded formulations2011-Innovated bi-layered sustained release tablets for the first time2012-Acquired Pure and Cure Healthcare Private Limited to expand capacity and capabilities2013-Innovated tablet-in-tablet sustained release tablets for the first time-Acquired Malik Lifesciences Private Limited manufacturing sites to expand capacity and capabilities-Expanded into the African market2015-Expanded into the Asian market-Established research and development laboratory in Mumbai, Maharashtra to venture into regulated market2016-Maxcure Nutravedics Limited received US-NSF certification2019-Investment by Ruby QC Investment Holdings Pte. Ltd. in our Company to become a minority shareholder2021-Acquired Parabolic Drugs to form Akums Lifesciences Limited and ventured into APIs-Acquisition of a facility at Kotdwar, Uttarakhand by Akums Healthcare Limited2022-Plant at 19, 20, 21, Sector 6A, SIDCUL, Haridwar, Uttarakhand and plant at 2, 3, 4,5, Sector 6B, SIDCUL, Haridwar, Uttarakhand accredited European Union-Good Manufacturing Practices, qualifying for exports to European markets-Acquisition of a facility in Haridwar, Uttarakhand by Akums Healthcare Limited and a facility in Baddi, Himachal Pradesh by Pure and Cure Healthcare Private Limited2023-Acquisition of another facility in Baddi, Himachal Pradesh by Pure and Cure Healthcare Private Limited-Merger of Akums Lifesciences Limited with Pure and Cure Healthcare Private Limited

Read More

Parent Organisation

Akums Drugs & Pharmaceuticals Ltd.

Founded

19/04/2004

Managing Director

Mr.Sanjeev Jain

NSE Symbol

AKUMSEQ

FAQ

The current price of Akums Drugs and Pharmaceuticals Ltd is ₹ 568.05.

The 52-week high for Akums Drugs and Pharmaceuticals Ltd is ₹ 582.00 and the 52-week low is ₹ 561.10.

The market capitalization of Akums Drugs and Pharmaceuticals Ltd is currently ₹ 8940.77. This value can fluctuate based on stock price movements and changes in the number of shares outstanding.

To buy Akums Drugs and Pharmaceuticals Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.

To invest in Akums Drugs and Pharmaceuticals Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Akums Drugs and Pharmaceuticals Ltd shares.

The CEO of Akums Drugs and Pharmaceuticals Ltd is Mr.Sanjeev Jain, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.

OPEN FREE* DEMAT ACCOUNT